

# SARC SEMIANNUAL MEETING

**FRIDAY, MAY 30, 2025 ♦ 7:30 AM-12 NOON CENTRAL**

Northwestern Memorial Hospital, Feinberg Conference Center 3<sup>rd</sup> Floor  
251 E. Huron Street, Chicago, IL, USA

<b>7:30-9:00 am</b>	<b>Breakfast &amp; Networking</b>	<b>Feinberg Krumlovsky Atrium</b>
<b>9:00-9:05 am</b>	<b>Welcome &amp; Meeting Overview</b>	<b>Feinberg ABCD Conference Room</b>
	<u>Opening Remarks:</u>	<b>Jonathan Fletcher MD</b> (SARC CSO; Harvard), <b>Scott Okuno MD</b> (SARC CMO; Mayo Clinic), <b>Seth Pollack MD</b> (Northwestern U.), <b>Steven Young</b> (SARC CEO)
<b>9:05-9:50 am</b>	<b>Neoadjuvant Immune Checkpoint Blockade for UPS, Myxofibrosarcoma, and De-Differentiated Liposarcoma: The New Standard of Care?</b>	
	<u>Moderators:</u>	<b>Sandra D'Angelo MD</b> (MSKCC) <b>Anusha Kalbasi MD</b> (Stanford U.) <b>Richard Riedel MD</b> (Duke U.)
	<b>Results of SU2C-SARC032 Ph II RCT Neoadjuvant Pembrolizumab w/RT &amp; Adjuvant Pembrolizumab in STS</b>	
	<b>Debate: Neoadjuvant Immune Checkpoint Blockade for UPS, MFS, and DDLPS</b>	
	<u>Proponent:</u>	<b>Nam Bui MD</b> (Stanford U.)
	<u>Opponent:</u>	<b>Aisha Miah MBBS PhD</b> (Royal Marsden)
<b>9:50-10:15 am</b>	<b>SARC Studies &amp; Programs</b>	<b>Presenters (bolded)</b>
	<u>Session Chair:</u>	<b>Scott Okuno MD</b>
	<b>Clinical Trials Development Committee</b>	<b>Greg Cote MD PhD</b> (MGH), <b>Elizabeth Davis MD</b> (Vanderbilt U.), <b>Brian Van Tine MD PhD</b> (WUSTL)
	<b>Investigator-Initiated, SARC-Sponsored Clinical Trials:</b>	
	• <u>Open/Enrolling:</u>	
	○ <b>SARC044 Ph II Bezuclastinib w/Sunitinib in GIST</b>	<b>Candace Haddox MD</b> (PI: Dana-Farber Cancer Inst.)
	• <u>Launching in 2025:</u>	
	○ <b>SARC045 Ph II Tebentafusp HLA-A*01:01 Positive Advanced CCS</b> PI: Evan Rosenbaum MD (MSKCC)	<b>Andrea Napolitano MD</b> (Co-PI: Royal Marsden)
	○ <b>SARC046 Ph II Nab-Sirolimus in EHE</b>	<b>Michael Wagner MD</b> (PI: Dana-Farber Cancer Inst.)
	• <u>Open/Fully Enrolled:</u>	<u>In Brief:</u> <b>Scott Okuno MD</b>
	○ <b>SARC037 Ph II Trabectedin w/Irinotecan &amp; 18F-FLT Imaging in ES</b> PI: P. Grohar MD PhD (U. Michigan)	
	○ <b>SARC038 Ph II Regorafenib &amp; Nivolumab in OS</b> PI: F. Navid MD (CHLA), Co-PI: L. Davis MD (OSU)	
	○ <b>SARC041 Ph III RCT Abemaciclib vs. Placebo in Advanced DDLPS</b>	<b>Mark Dickson MD</b> (PI: MSKCC)
	<b>Sarcoma Centers Directory (SCD)</b>	<b>SCD Steering Committee</b>
<b>10:15-10:30 am</b>	<b>Break</b>	
<b>10:30-11:15 am</b>	<b>Approaches for Sarcoma Patients with Oligometastatic Pulmonary Disease</b>	
	<u>Session Chair:</u>	<b>Kurt Weiss MD</b> (U. of Pittsburgh)
	<u>Discussion: Panel &amp; Audience:</u>	<b>Meena Bedi MD</b> (Medical College of Wisconsin), <b>Abha Gupta MD</b> (Hospital for Sick Children, Princess Margaret Hospital), <b>Robin Jones MD</b> (Royal Marsden), <b>Samuel Kim MD</b> (Northwestern U.), <b>Breelyn Wilky MD</b> (U. of Colorado)

**Program continues on page 2**

Co-Chairs: **Patrick Schöffski MD MPH** (Leuven Cancer Inst.)  
**Breelyn Wilky MD** (U. of Colorado)

This CME activity is provided by PeerView and supported by an independent educational grant from SpringWorks Therapeutics, Inc.

## Thank You to Our Sponsors

### Silver



### Bronze

IMMUNOCORE



### Other Support

